Zobrazeno 1 - 10
of 203
pro vyhledávání: '"Marta Schirripa"'
Autor:
Carlo Signorelli, Maria Alessandra Calegari, Michele Basso, Annunziato Anghelone, Jessica Lucchetti, Alessandro Minelli, Lorenzo Angotti, Ina Valeria Zurlo, Marta Schirripa, Mario Giovanni Chilelli, Cristina Morelli, Emanuela Dell’Aquila, Antonella Cosimati, Donatello Gemma, Marta Ribelli, Alessandra Emiliani, Domenico Cristiano Corsi, Giulia Arrivi, Federica Mazzuca, Federica Zoratto, Maria Grazia Morandi, Fiorenza Santamaria, Rosa Saltarelli, Enzo Maria Ruggeri
Publikováno v:
Current Oncology, Vol 30, Iss 6, Pp 5456-5469 (2023)
Background: Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) and trifluridine/tipiracil (T) are two key new treatment options with
Externí odkaz:
https://doaj.org/article/afc24ec0fba644d393d93c2ccdec9fdd
Autor:
Fabrizio Nelli, Agnese Fabbri, Antonella Virtuoso, Diana Giannarelli, Julio Rodrigo Giron Berrios, Eleonora Marrucci, Cristina Fiore, Marta Schirripa, Carlo Signorelli, Mario Giovanni Chilelli, Francesca Primi, Gloria Pessina, Federica Natoni, Maria Assunta Silvestri, Enzo Maria Ruggeri
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 5103-5115 (2023)
(1) Background: The clinical implications of COVID-19 outbreaks following SARS-CoV-2 vaccination in immunocompromised recipients are a worldwide concern. Cancer patients on active treatment remain at an increased risk of developing breakthrough infec
Externí odkaz:
https://doaj.org/article/99101d499d93422bac199df094e1c46f
Autor:
Enzo Maria Ruggeri, Fabrizio Nelli, Diana Giannarelli, Agnese Fabbri, Julio Rodrigo Giron Berrios, Antonella Virtuoso, Eleonora Marrucci, Marco Mazzotta, Marta Schirripa, Carlo Signorelli, Mario Giovanni Chilelli, Francesca Primi, Cristina Fiore, Valentina Panichi, Giuseppe Topini, Maria Assunta Silvestri
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract The aim of this study was to evaluate the association of circulating lymphocytes profiling with antibody response in cancer patients receiving the third dose of COVID-19 mRNA-BNT162b2 vaccine. Immunophenotyping of peripheral blood was used t
Externí odkaz:
https://doaj.org/article/e9d4174022ab40a593fe25e6eb7688c7
Autor:
Nicola Reggidori, Laura Bucci, Valentina Santi, Benedetta Stefanini, Lorenzo Lani, Davide Rampoldi, Giorgia Ghittoni, Fabio Farinati, Alberto Masotto, Bernardo Stefanini, Andrea Mega, Elisabetta Biasini, Francesco Giuseppe Foschi, Gianluca Svegliati-Baroni, Angelo Sangiovanni, Claudia Campani, Giovanni Raimondo, Gianpaolo Vidili, Antonio Gasbarrini, Ciro Celsa, Mariella Di Marco, Edoardo G. Giannini, Rodolfo Sacco, Maurizia Rossana Brunetto, Francesco Azzaroli, Donatella Magalotti, Filomena Morisco, Gian Ludovico Rapaccini, Gerardo Nardone, Alessandro Vitale, Franco Trevisani, Maurizio Biselli, Paolo Caraceni, Annagiulia Gramenzi, Francesca Benevento, Alessandro Granito, Luca Muratori, Fabio Piscaglia, Francesco Tovoli, Gloria Allegrini, Calogero Cammà, Giuseppe Cabibbo, Carmelo Marco Giacchetto, Paolo Giuffrida, Maria Vittoria Grassini, Mauro Grova, Gabriele Rancatore, Caterina Stornello, Valentina Adotti, Tancredi Li Cavoli, Fabio Marra, Martina Rosi, Vittoria Bevilacqua, Alberto Borghi, Lucia Napoli, Fabio Conti, G.L. Frassineti, Maria Teresa Migliano, Nicoletta de Matthaeis, Francesca Romana Ponziani, Gabriele Missale, Andrea Olivani, Mario Capasso, Valentina Cossiga, Maria Guarino, Ester Marina Cela, Antonio Facciorusso, Camilla Graziosi, Valentina Lauria, Giorgio Pelecca, Marta Schirripa, Fabrizio Chegai, Armando Raso, Alessio Bozzi, Maria Stella Franzè, Carlo Saitta, Assunta Sauchella, Elton Dajti, Federico Ravaioli, Maria Corina Plaz Torres, Giulia Pieri, Filippo Oliveri, Gabriele Ricco, Veronica Romagnoli, Alessandro Inno, Fabiana Marchetti, Pietro Coccoli, Antonio Malerba, Alberta Cappelli, Rita Golfieri, Cristina Mosconi, Matteo Renzulli
Publikováno v:
JHEP Reports, Vol 5, Iss 8, Pp 100784- (2023)
Background & Aims: Alcohol abuse and metabolic disorders are leading causes of hepatocellular carcinoma (HCC) worldwide. Alcohol-related aetiology is associated with a worse prognosis compared with viral agents, because of the lower percentage of pat
Externí odkaz:
https://doaj.org/article/994809fcb7eb4d6c91173f05293807e2
Autor:
Massimo Iavarone, Eleonora Alimenti, Toshifumi Tada, Shigeo Shimose, Goki Suda, Changhoon Yoo, Caterina Soldà, Fabio Piscaglia, Giulia Tosetti, Fabio Marra, Caterina Vivaldi, Fabio Conti, Marta Schirripa, Hideki Iwamoto, Takuya Sho, So Heun Lee, Mario Domenico Rizzato, Matteo Tonnini, Margherita Rimini, Claudia Campani, Gianluca Masi, Francesco Foschi, Mariangela Bruccoleri, Takumi Kawaguchi, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Shinya Fukunishi, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Andrea Casadei-Gardini, Pietro Lampertico
Publikováno v:
Liver Cancer, Pp 1-1 (2023)
Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and compli
Externí odkaz:
https://doaj.org/article/93da06996cb6459c9ed74984e1ecb6e5
Autor:
Giuseppe Nicolò Fanelli, Carlo Alberto Dal Pozzo, Ilaria Depetris, Marta Schirripa, Stefano Brignola, Paola Biason, Mariangela Balistreri, Luca Dal Santo, Sara Lonardi, Giada Munari, Fotios Loupakis, Matteo Fassan
Publikováno v:
Cancer Cell International, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Colorectal cancer (CRC) is a complex and molecularly heterogeneous disease representing one of the most frequent causes of cancer-related death worldwide. About 8–15% of CRCs harbor a mutation in BRAF gene, a proto-oncogene involved in cel
Externí odkaz:
https://doaj.org/article/7de1e6340d0542cfb9107c560ec468f4
Autor:
Yuji Miyamoto, Marta Schirripa, Mitsukuni Suenaga, Shu Cao, Wu Zhang, Satoshi Okazaki, Martin D Berger, Satoshi Matsusaka, Dongyun Yang, Yan Ning, Hideo Baba, Fotios Loupakis, Sara Lonardi, Filippo Pietrantonio, Beatrice Borelli, Chiara Cremolini, Toshiharu Yamaguchi, Heinz-Josef Lenz
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0239439 (2020)
Activin/myostatin signaling has a critical role not only in cachexia but also in tumor angiogenesis. Cachexia is a frequent complication among patients with advanced cancer and heavily pretreated patients. We aimed to evaluate the prognostic signific
Externí odkaz:
https://doaj.org/article/baae7085fd3248ec9c83507338f3ccac
Autor:
Francesca Battaglin, Marta Schirripa, Federica Buggin, Filippo Pietrantonio, Federica Morano, Giorgia Boscolo, Giuseppe Tonini, Eufemia Stefania Lutrino, Jessica Lucchetti, Lisa Salvatore, Alessandro Passardi, Chiara Cremolini, Ermenegildo Arnoldi, Mario Scartozzi, Nicoletta Pella, Luca Boni, Francesca Bergamo, Vittorina Zagonel, Fotios Loupakis, Sara Lonardi
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Few data are available regarding the treatment of metastatic colorectal cancer elderly patients with anti-EGFR agents in combination with chemotherapy. FOLFOX plus panitumumab is a standard first-line option for RAS wild-type meta
Externí odkaz:
https://doaj.org/article/20dd46d392e5481ba7500fbb282db4da
Autor:
Chiara Cremolini, Federica Marmorino, Fotios Loupakis, Gianluca Masi, Carlotta Antoniotti, Lisa Salvatore, Marta Schirripa, Luca Boni, Vittorina Zagonel, Sara Lonardi, Giuseppe Aprile, Emiliano Tamburini, Vincenzo Ricci, Monica Ronzoni, Filippo Pietrantonio, Chiara Valsuani, Gianluca Tomasello, Alessandro Passardi, Giacomo Allegrini, Samantha Di Donato, Daniele Santini, Alfredo Falcone, on behalf of all the investigators of the Gruppo Oncologico del Nord Ovest
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy backbones may be chosen, including one to three drugs, based on patients’ general co
Externí odkaz:
https://doaj.org/article/1a0fb5b337924a1fba12ac54e2cae3ab
Autor:
Alessio Amatu, Marta Schirripa, Federica Tosi, Sara Lonardi, Katia Bencardino, Erica Bonazzina, Laura Palmeri, Damiano Alfio Patanè, Elio Gregory Pizzutilo, Benedetta Mussolin, Francesca Bergamo, Giulia Alberti, Rossana Intini, Letizia Procaccio, Marco Arese, Silvia Marsoni, Michele Nichelatti, Vittorina Zagonel, Salvatore Siena, Alberto Bardelli, Fotios Loupakis, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Ludovic Barault
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: Regorafenib improves progression free survival (PFS) in a subset of metastatic colorectal cancer (mCRC) patients, although no biomarkers of efficacy are available. Circulating methylated DNA (cmDNA) assessed by a five-gene panel was previ
Externí odkaz:
https://doaj.org/article/03adbb2e3faf4c54b1f03312367d97e5